Feb 25 – Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes ‌in India after patent expiry of the Ozempic active ingredient in late March, it said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results